IGC Pharma (IGC) Receivables - Net (2016 - 2025)
IGC Pharma (IGC) has disclosed Receivables - Net for 15 consecutive years, with $41000.0 as the latest value for Q3 2025.
- On a quarterly basis, Receivables - Net fell 6.82% to $41000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $41000.0, a 6.82% decrease, with the full-year FY2025 number at $34000.0, down 12.82% from a year prior.
- Receivables - Net was $41000.0 for Q3 2025 at IGC Pharma, down from $87000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $251000.0 in Q4 2022 to a low of $28000.0 in Q2 2024.
- A 5-year average of $117578.9 and a median of $125000.0 in 2022 define the central range for Receivables - Net.
- Peak YoY movement for Receivables - Net: plummeted 87.56% in 2024, then skyrocketed 210.71% in 2025.
- IGC Pharma's Receivables - Net stood at $164000.0 in 2021, then soared by 53.05% to $251000.0 in 2022, then crashed by 63.35% to $92000.0 in 2023, then plummeted by 46.74% to $49000.0 in 2024, then decreased by 16.33% to $41000.0 in 2025.
- Per Business Quant, the three most recent readings for IGC's Receivables - Net are $41000.0 (Q3 2025), $87000.0 (Q2 2025), and $34000.0 (Q1 2025).